Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001442 · ClinicalTrials.gov registry record · Phase 1
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Biotest Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01001442 is a Phase 1 study that has completed, run by Biotest Pharmaceuticals Corporation. The registered enrollment target is 35 participants.
The verdict
NCT01001442, a Phase 1 study, has completed, sponsored by Biotest Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This Phase I/IIa clinical study is to test safety and anti-tumor activity of BT062 to define the best dose in treating patients with relapsed or refractory multiple myeloma with multiple doses of BT062.
Interventions
- DRUG BT062
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-08 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01001442
The ClinicalTrials.gov registry entry for NCT01001442 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biotest Pharmaceuticals Corporation, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BT062 is the first listed.
NCT01001442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01001442 about?
NCT01001442 is a clinical study titled "Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma". This Phase I/IIa clinical study is to test safety and anti-tumor activity of BT062 to define the best dose in treating patients with relapsed or refractory multiple myeloma with multiple doses of BT062.
What is the current status of trial NCT01001442?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2010-08. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01001442?
The interventions under investigation include: BT062 (DRUG).
Who is sponsoring clinical trial NCT01001442?
This trial is sponsored by Biotest Pharmaceuticals Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.